Jennifer Viera | Investor Relations |
Jay Luly | President & Chief Executive Officer |
Scott Rottinghaus | Chief Medical Officer |
Paul Mellett | Chief Financial Officer |
Tara Kieffer | Senior Vice President, New Product Strategy & Development |
Yasmeen Rahimi | Piper Sandler |
Brian Abrahams | RBC Capital Markets |
Roy Buchanan | JMP Securities |
Liisa Bayko | Evercore ISI |
Brian Skorney | Baird |
Thomas Yip | H.C. Wainwright |
Roanna Ruiz | SVB Securities |
Hannah Adeoye | JPMorgan |
Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Second Quarter Ended March 31, 2022 Financial Results Conference Call. At this time, all participants are in a listen only mode. There will be a question-and-answer session at the end of prepared remarks. Please be advised that these call is being recorded.
I would now like to turn the conference over to Jennifer Viera, Investor Relations.